TGF-beta Antagonists: Why Suppress a Tumor Suppressor?

J Clin Invest. 2002 Jun;109(12):1533-6. doi: 10.1172/JCI15970.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review
  • Comment

MeSH terms

  • Animals
  • DNA-Binding Proteins / metabolism
  • Drug Design
  • Humans
  • Immunoglobulin Fc Fragments / genetics
  • Immunoglobulin Fc Fragments / metabolism
  • Immunoglobulin Fc Fragments / physiology
  • Immunoglobulin G / genetics
  • Immunoglobulin G / metabolism
  • Immunoglobulin G / physiology
  • Liver Neoplasms / secondary*
  • Lung Neoplasms / secondary*
  • Mammary Neoplasms, Animal / pathology
  • Mammary Neoplasms, Animal / prevention & control*
  • Melanoma, Experimental / pathology
  • Melanoma, Experimental / prevention & control*
  • Protein-Serine-Threonine Kinases
  • Receptor, Transforming Growth Factor-beta Type II
  • Receptors, Transforming Growth Factor beta / genetics
  • Receptors, Transforming Growth Factor beta / immunology
  • Receptors, Transforming Growth Factor beta / metabolism
  • Receptors, Transforming Growth Factor beta / physiology*
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / metabolism
  • Recombinant Fusion Proteins / physiology
  • Signal Transduction*
  • Smad4 Protein
  • Trans-Activators / metabolism
  • Transforming Growth Factor beta / antagonists & inhibitors*

Substances

  • DNA-Binding Proteins
  • Immunoglobulin Fc Fragments
  • Immunoglobulin G
  • Receptors, Transforming Growth Factor beta
  • Recombinant Fusion Proteins
  • SMAD4 protein, human
  • Smad4 Protein
  • Trans-Activators
  • Transforming Growth Factor beta
  • Protein-Serine-Threonine Kinases
  • Receptor, Transforming Growth Factor-beta Type II